Apomorphine HCl
Dopamine agonist / Archetypal dopamine pan-receptor agonist. Displays anti-Parkinsons activity in vivo.1 Protects against MPTP-induced neurotoxicity in a mouse model.2 In clinical use for Parkinson’s disease.4,5
Biochemicals & reagents
41372-20-7
R-(-)-6aβ-aporphine-10,11-diol hydrochloride hemihydrate
1) Merck Index 14:746 2) Millan et al. (2002), Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes; J. Pharmacol. Exp. Therap., 303 791 3) Grunblatt et al. (1999), Apomorphine protects against MPTP-induced neurotoxicity in mice.; Mov. Discord, 14 612 4) Auffret et al. (2017), Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations; J. Neurol. Sci, 372 279 5) Jenner and Katzenschlager (2016), Apomorphine – pharmacological properties and clinical trials in Parkinson’s disease; Parkinsoism. Related. Disord., 33 Suppl. 1:S13
RT
TARGET: Monoamine receptor; Dopamine; GPCR -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration